Albumin Infusion Targets on Mortality in Patients With Abdominal Sepsis
Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Mar 7, 2025
Trial Information
Current as of April 23, 2025
Completed
Keywords
ClinConnect Summary
Research Background Introduction to Sepsis and Abdominal Sepsis Sepsis is a life-threatening condition characterized by organ dysfunction due to a dysregulated immune response to infection. Abdominal sepsis, originating from intra-abdominal infections, is particularly challenging due to its high morbidity and mortality rates. The mortality rate for abdominal sepsis ranges from 7.6% to 36.0%, and it can reach up to 50% if it progresses to septic shock. The presence of hypoalbuminemia further complicates the clinical course and prognosis of sepsis patients.
Role of Albumin in Sepsis Albumin ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients admitted to the Intensive Care Department of Southern Hospital of Southern Medical University from September 2017 to June 2022;
- • Age ≥ 18 years old;
- • Meeting the diagnostic criteria for abdominal infection;
- • Patients who meet the diagnostic criteria for sepsis/septic shock;
- • Complicated with hypoalbuminemia, i.e. plasma albumin\<30g/L after admission;
- • Human serum albumin injection was infused within 24 hours after check-in into the ICU.
- Exclusion Criteria:
- • Pregnant or lactating women
- • Patients who have not been able to obtain relevant diagnosis and treatment information after ICU check-in
- • Patients who repeatedly stay in the ICU
- • ICU hospitalization time is less than 24 hours
- • Pathological conditions that require albumin treatment in clinical practice (cirrhosis with ascites, post liver transplantation, intestinal malabsorption syndrome, nephrotic syndrome, burns);
About Nanfang Hospital, Southern Medical University
Nanfang Hospital, affiliated with Southern Medical University, is a leading medical institution in China renowned for its comprehensive clinical services and commitment to advancing healthcare through research and education. As a clinical trial sponsor, Nanfang Hospital leverages its state-of-the-art facilities and a multidisciplinary team of expert researchers to conduct innovative studies aimed at improving patient outcomes and contributing to the global medical community. The hospital's focus on ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and scientific rigor.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported